Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

chronic lung disease

- PMLiVE

FDA rejects AZ’s diabetes combination

Wants to see more trial data on saxagliptin / dapagliflozin

- PMLiVE

AZ halts durvalumab combination trials on safety grounds

Saysmove is a precautionary step after respiratory disease reports

- PMLiVE

Novartis’ Cosentyx effective in psoriatic arthritis study

Further supports drugs ability to reduce progression of damage to joints

- PMLiVE

AZ opens new research centre with Cancer Research UK

MedImmune partners with CRUK in Cambridge-based R&D hub

AZ signs £11.5m bioinformatics deal with Manchester University

Five-year programme will focus on personalised health research

- PMLiVE

FDA approval keeps AZ on track with ambitious Brilinta plans

Receives additional indication for use in heart attack patients

AstraZeneca appoints Sean Bohen as chief medical officer

Dr Bohen will join the firm from Genentech

- PMLiVE

AZ and Peregrine join forces on cancer trial

Another oncology deal for the company after a recent spate of deals

- PMLiVE

Jardiance is first diabetes drug to improve CV outcomes

Lilly/Boehringer drug could gain market share boost from new data

- PMLiVE

AZ adds cancer vaccine to immuno-oncology portfolio

Firm's biologics unit adds to string of oncology deals in 2015

- PMLiVE

MedImmune appoints Dr Christopher Rhodes

Will head cardiovascular and metabolic diseaseresearch for the AZ unit

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links